retatrutide and heart issues rate: what the clinical data actually shows RETATRUTIDE: The Triple-Agonist Rewriting Obesity

This dual mechanism, reduced intake plus increased expenditure, explains why the Phase 2 data showed such dramatically higher weight loss percentages than any dual agonist trial

Los aGLP-1 estn financiados en terapia combinada en pacientes con DM2 e IMC 30 kg/m 2

Weight loss accelerates during this period, which compounds the glucose benefits

Direct Myocardial Effects Although the presence of functional GLP-1 receptors on human ventricular cardiomyocytes remains a matter of debate, preclinical studies suggest potential direct cardioprotective effects

This maintains the weekly rhythm while allowing the previous medication to clear

Sridhar VS, Dubrofsky L, Boulet J, Cherney DZ